• Product NameIvosidenib
• Brief DescriptionInhibitors
• Purification99.48%
• Biological ActivityIvosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells.
• Target NameDehydrogenase inhibitor
• CAS No. 1448347-49-6
• Calculated MW 582.97
• Formulation C28H22ClF3N6O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:C1CC(=O)N([C@@H]1C(=O)N(C2=CC(=CN=C2)F)[C@@H](C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N
  Pathways:Metabolism
  Receptor:IDH1
  Boling pt:
  Melting pt:
  Solubility:DMSO: 39 mg/mL
  Appearance:White powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Agresta Samuel V, et al. From PCT Int. Appl. (2015), WO 2015127172 A1 20150827.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting